Literature DB >> 2869502

Shuttle-box deficits induced by inescapable shocks in rats: reversal by the beta-adrenoreceptor stimulants clenbuterol and salbutamol.

P Martin, P Soubrie, P Simon.   

Abstract

Beta-adrenoreceptor stimulants such as salbutamol and clenbuterol have been reported to be effective in depressive states and to share many actions with classical antidepressants in animals. To further explore the antidepressant activity of these drugs, we investigated their effects in rats subjected to helplessness training. Rats were first exposed to inescapable shock pre-treatment (60 shocks, 15 sec duration, 1 mA every minute +/- 15 sec) and 48 hr later, shuttle-box training (30 trials/day, ITI: 30 sec) was initiated in order to evaluate escape and avoidance deficits. Rats pretreated with inescapable shocks exhibited escape and avoidance deficits when tested for subsequent responding in a shuttle-box. The deficits are particularly marked at the third training session. Daily IP injections of clenbuterol (total daily dose: 0.5 and 0.75 mg/kg) and salbutamol (16 and 24 mg/kg) prevented escape deficits as did daily injections of classical antidepressants such as desipramine (16 and 24 mg/kg/day) and clomipramine (16 and 24 mg/kg/day). These data extend previous results bearing on the similarity of action of beta receptor stimulants and tricyclic antidepressants and further support the notion of a close relationship between noradrenergic function, more especially beta-adrenoreceptors, and "helpless" behavior.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869502     DOI: 10.1016/0091-3057(86)90334-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  13 in total

1.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  Noradrenergic and opioid mediation of tricyclic-induced reversal of escape deficits caused by inescapable shock pretreatment in rats.

Authors:  P Martin; P Soubrié; P Simon
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Behaviour of a genetic mouse model of depression in the learned helplessness paradigm.

Authors:  Laure Bougarel; Jérôme Guitton; Luc Zimmer; Jean-Marie Vaugeois; Malika El Yacoubi
Journal:  Psychopharmacology (Berl)       Date:  2011-02-22       Impact factor: 4.530

4.  1-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonist in the learned helplessness paradigm in rats.

Authors:  P Martin
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 5.  Salbutamol in the 1980s. A reappraisal of its clinical efficacy.

Authors:  A H Price; S P Clissold
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

6.  Effects of centrally acting beta adrenergic agonists on discrete trial conditioned avoidance behavior in rats.

Authors:  J F McElroy; J J Stimmel; J M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  Reversal of helpless behavior by serotonin uptake blockers in rats.

Authors:  P Martin; P Soubrié; A J Puech
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

8.  Differential sensitivity to the effects of albuterol on locomotor activity and operant behavior.

Authors:  J M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Differential effects of chronic antidepressant treatment on shuttle box escape deficits induced by uncontrollable stress.

Authors:  Gerald Valentine; Antonia Dow; Mounira Banasr; Brian Pittman; Ronald Duman
Journal:  Psychopharmacology (Berl)       Date:  2008-07-06       Impact factor: 4.530

10.  VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants.

Authors:  Jennifer L Warner-Schmidt; Ronald S Duman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.